Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we’re talking about! Here is some more information if you’re curious.
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
AstraZeneca starts the big fight in EGFR-positive lung cancer
Company: AstraZeneca (AZN)
Disease: EGFR-mutant non-small cell lung cancer
News: AZN announced approval for osimertinib in the treatment of previously untreated EGFR-positive non-small cell lung cancer. This came as little surprise, given the findings from the phase 3 FLAURA study, which demonstrated superior progression-free survival for osimertinib over erlotinib/gefitinib in the first-line setting.
Looking forward: Now the big fight begins, with osimertinib out in the lead. A few days ago, I prepared an article describing the coming fight for first-line dominance between osimertinib and dacomitinib (read that here). This is definitely going to give AZN a huge boost in the fight, being the first to market. That and for all intents and purposes, it appears as though osimertinib is the better drug. But it still remains unclear at this time whether clinicians should hold the “best” drug for later lines of therapy so they can extend their options. And for that we’ll need longer-term follow-up from the FLAURA study.
Top Biotech Stocks To Buy For 2019: STARWOOD PROPERTY TRUST, INC.(STWD)
- [By WWW.MONEYSHOW.COM]
Starwood Property Trust (STWD) is a finance REIT, which means it makes or owns real estate mortgages rather than owning commercial property. The bulk of Starwood Property’s business is to make and hold commercial property mortgages.
Top Biotech Stocks To Buy For 2019: Omega Protein Corporation(OME)
- [By Lisa Levin]
Omega Protein Corporation (NYSE: OME) was down, falling around 20 percent to $17.47 after the company reported weaker-than-expected results for its fourth quarter.
- [By Lisa Levin]
Omega Protein Corporation (NASDAQ: OME) shares dropped 21 percent to $20.65 after the company posted weak Q4 earnings.
Shares of Endeavour Silver Corp (NYSE: EXK) were down around 22 percent to $3.41. Endeavour Silver reported a Q4 loss of $5.2 million.
Top Biotech Stocks To Buy For 2019: Novellus Systems Inc.(NVLS)
- [By Paul Ausick]
Nivalis Therapeutics Inc. (NASDAQ: NVLS) dropped 60% on Tuesday to post a new 52-week low of $2.50 after closing at $6.25 on Monday. The stock’s 52-week high is $9.45. Volume of about 4.2million was about 60 times the daily average of around 75,000 shares. The company reported a failed mid-stage trial on its treatment for cystic fibrosis.
- [By Chris Lange]
Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.
- [By Lisa Levin]
Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.